{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:50:31Z","timestamp":1788281431185,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["201603PJT"],"award-info":[{"award-number":["201603PJT"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Opioid overdose epidemic is a public health crisis that is impacting communities around the world. Overdose education and naloxone distribution programs equip and train lay people to respond in the event of an overdose. We aimed to understand factors to consider for the design of naloxone distribution programs in point-of-care settings from the point of view of community stakeholders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We hosted a multi-stakeholder co-design workshop to elicit suggestions for a naloxone distribution program. We recruited people with lived experience of opioid overdose, community representatives, and other stakeholders from family practice, emergency medicine, addictions medicine, and public health to participate in a full-day facilitated co-design discussion wherein large and small group discussions were audio-recorded, transcribed and analysed using thematic approaches.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of twenty-four participants participated in the multi-stakeholder workshop from five stakeholder groups including geographic and setting diversity. Collaborative dialogue and shared storytelling revealed seven considerations for the design of naloxone distribution programs specific to training needs and the provision of naloxone, these are: recognizing overdose, how much naloxone, impact of stigma, legal risk of responding, position as conventional first aid, friends and family as responders, support to call 911.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To create an naloxone distribution program in emergency departments, family practice and substance use treatment services, stigma is a central design consideration for training and naloxone kits. Design choices that reference the iconography, type, and form of materials associated with first aid have the potential to satisfy the need to de-stigmatize overdose response.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12889-023-15554-6","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:33:06Z","timestamp":1684161186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Considerations for the design of overdose education and naloxone distribution interventions: results of a multi-stakeholder workshop"],"prefix":"10.1186","volume":"23","author":[{"given":"Kate","family":"Sellen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet A.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Leece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Handford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Goso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Klaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Shahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Milos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercy","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Strike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Orkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"SOONER Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"15554_CR1","volume-title":"Opioid- and Stimulant-related Harms in Canada. Canada.ca","author":"Public Health Agency of Canada","year":"2020","unstructured":"Public Health Agency of Canada. Opioid- and Stimulant-related Harms in Canada. Canada.ca. 2020. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants\/. [Cited 2021 Jan 7]."},{"issue":"7","key":"15554_CR2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/add.13326","volume":"111","author":"R McDonald","year":"2016","unstructured":"McDonald R, Strang J. Are take\u2010home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction . 2016;111(7):1177\u201387.\u00a0Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/add.13326. [Cited 2021 Mar 15].","journal-title":"Addiction."},{"issue":"jan30 5","key":"15554_CR3","doi-asserted-by":"publisher","first-page":"f174","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2013","unstructured":"Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346(jan30 5):f174\u20134. Available from: https:\/\/www.bmj.com\/content\/346\/bmj.f174. [Cited 2021 Jan 7].","journal-title":"BMJ"},{"issue":"1","key":"15554_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/PHH.0000000000000538","volume":"24","author":"SC Heavey","year":"2018","unstructured":"Heavey SC, Burstein G, Moore C, Homish GG. Overdose education and naloxone distribution program attendees: who attends, what do they know, and how do they feel? J Public Health Manag Pract. 2018;24(1):63.","journal-title":"J Public Health Manag Pract"},{"issue":"8","key":"15554_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2105\/AJPH.2021.306306","volume":"111","author":"A Razaghizad","year":"2021","unstructured":"Razaghizad A, Windle SB, Filion KB, Gore G, Kudrina I, Paraskevopoulos E, Kimmelman J, Martel MO, Eisenberg MJ. The effect of overdose education and naloxone distribution: an umbrella review of systematic reviews. Am J Public Health. 2021;111(8):e1-2.","journal-title":"Am J Public Health"},{"key":"15554_CR6","first-page":"1","volume-title":"A report prepared by: The Ontario Drug Policy Research Network Public Health Ontario Centre on Drug Policy Evaluation","author":"Ontario Drug Policy Research Network","year":"2020","unstructured":"Ontario Drug Policy Research Network. A report prepared by: The Ontario Drug Policy Research Network Public Health Ontario Centre on Drug Policy Evaluation. 2020. p. 1\u201324. Available from: https:\/\/www.publichealthontario.ca\/-\/media\/documents\/o\/2020\/opioid-mortality-covid-surveillance-report.pdf?la=en. [Cited 2021 Jan 15]."},{"issue":"6","key":"15554_CR7","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s11524-020-00486-y","volume":"97","author":"LN Rodda","year":"2020","unstructured":"Rodda LN, West KL, LeSaint KT. Opioid Overdose\u2013Related Emergency Department Visits and Accidental Deaths during the COVID-19 Pandemic. J Urban Health. 2020;97(6):808\u201313. Available from:\u00a0https:\/\/link.springer.com\/article\/10.1007\/s11524-020-00486-y. [Cited 2021 Mar 15].","journal-title":"J Urban Health."},{"key":"15554_CR8","doi-asserted-by":"crossref","unstructured":"Wilkinson R, Hines L, Holland A, Mandal S, Phipps E. Rapid evidence review of harm reduction interventions and messaging for people who inject drugs during pandemic events: implications for the ongoing COVID-19 response. Harm Reduct J. 2020;17(1). Available from: https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-020-00445-5. [Cited 2021 Mar 15].","DOI":"10.1186\/s12954-020-00445-5"},{"issue":"16","key":"15554_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.2020.18543","volume":"324","author":"DF Haley","year":"2020","unstructured":"Haley DF, Saitz R. The Opioid Epidemic During the COVID-19 Pandemic. JAMA. 2020;324(16):1615. Available from: https:\/\/jamanetwork.com\/journals\/jama\/article-abstract\/2770985. [Cited 2021 Mar 15].","journal-title":"JAMA."},{"issue":"5","key":"15554_CR10","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2468-2667(18)30044-6","volume":"3","author":"MA Irvine","year":"2018","unstructured":"Irvine MA, Buxton JA, Otterstatter M, Balshaw R, Gustafson R, Tyndall M, et al. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. Lancet Public Health. 2018;3(5):e218\u201325. Available from: https:\/\/www.thelancet.com\/journals\/lanpub\/article\/PIIS2468-2667(18)30044-6\/fulltext. [Cited 2021 Jan 7].","journal-title":"Lancet Public Health."},{"key":"15554_CR11","unstructured":"Naloxone Distribution Environmental Scan. CRISM. 2019. Available from: https:\/\/crism.ca\/2019\/06\/13\/naloxone-distribution-environmental-scan\/. [Cited 2021 Jan 7]."},{"issue":"3","key":"15554_CR12","doi-asserted-by":"publisher","first-page":"e0230127","DOI":"10.1371\/journal.pone.0230127","volume":"15","author":"M Buresh","year":"2020","unstructured":"Buresh M, Gicquelais RE, Astemborski J, Kirk GD, Mehta SH, Genberg BL. Fatal overdose prevention and experience with naloxone: a cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland. PLoS One. 2020;15(3):e0230127.","journal-title":"PLoS One"},{"key":"15554_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.drugpo.2017.09.015","volume":"51","author":"SC Heavey","year":"2018","unstructured":"Heavey SC, Chang YP, Vest BM, Collins RL, Wieczorek W, Homish GG. Naloxone access and changes in opioid use behaviours. Int J Drug Policy. 2018;51:27\u201335.","journal-title":"Int J Drug Policy"},{"key":"15554_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-016-0068-3","volume":"12","author":"T Kerensky","year":"2017","unstructured":"Kerensky T, Walley AY. Opioid overdose prevention and naloxone rescue kits: what we know and what we don\u2019t know. Addict Sci Clin Pract. 2017;12:1\u20137.","journal-title":"Addict Sci Clin Pract"},{"key":"15554_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-019-0195-4","volume":"14","author":"RB Moss","year":"2019","unstructured":"Moss RB, Carlo DJ. Higher doses of naloxone are needed in the synthetic opioid era. Subst Abuse Treat Prev Policy. 2019;14:1\u20136.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"15554_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13011-021-00360-3","volume":"16","author":"ER Macleod","year":"2021","unstructured":"Macleod ER, Tajbakhsh I, Hamilton-Wright S, Laliberte N, Wiese JL, Matheson FI. \u201cThey\u2019re not doing enough.\u201d: women\u2019s experiences with opioids and naloxone in Toronto. Subst Abuse Treat Prev Policy. 2021;16:1\u20135.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"15554_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/pharmacy9010030","volume":"9","author":"A Cid","year":"2021","unstructured":"Cid A, Daskalakis G, Grindrod K, Beazely MA. What is known about community pharmacy-based take-home naloxone programs and program interventions? A scoping review. Pharmacy. 2021;9(1):30.","journal-title":"Pharmacy"},{"key":"15554_CR18","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.drugpo.2018.07.003","volume":"59","author":"K Tobin","year":"2018","unstructured":"Tobin K, Clyde C, Davey-Rothwell M, Latkin C. Awareness and access to naloxone necessary but not sufficient: examining gaps in the naloxone cascade. Int J Drug Policy. 2018;59:94\u20137.","journal-title":"Int J Drug Policy"},{"key":"15554_CR19","volume-title":"Opioid overdose: preventing and reducing opioid overdose mortality","author":"United Nations Office on Drugs and Crime","year":"2013","unstructured":"United Nations Office on Drugs and Crime. Opioid overdose: preventing and reducing opioid overdose mortality. 2013. Available from: https:\/\/www.unodc.org\/docs\/treatment\/overdose.pdf."},{"key":"15554_CR20","unstructured":"Opioid Overdose Prevention Programs Providing Naloxone to Laypersons \u2014 United States, 2014. 2021. Available from: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6423a2.htm. [Cited 2021 Jan 7]."},{"issue":"2","key":"15554_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jsat.2012.07.004","volume":"44","author":"AY Walley","year":"2013","unstructured":"Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat. 2013;44(2):241\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22980450\/. [Cited 2021 Jan 7].","journal-title":"J Subst Abuse Treat."},{"key":"15554_CR22","unstructured":"Health Canada. Federal actions on opioids to Date - Canada.ca. Canada.ca. 2020. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-use\/problematic-prescription-drug-use\/opioids\/federal-actions\/overview.html. [Cited 2021 Jan 7]."},{"key":"15554_CR23","unstructured":"Health Canada. Notice: Prescription Drug List (PDL): Naloxone - Canada.ca. Canada.ca. 2016. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/prescription-drug-list\/notice-naloxone.html. [Cited 2021 Jan 7]."},{"key":"15554_CR24","doi-asserted-by":"crossref","unstructured":"Strike C, Watson TM. Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. Int J Drug Policy. 2019;1(71):178\u201382.","DOI":"10.1016\/j.drugpo.2019.02.005"},{"issue":"4","key":"15554_CR25","doi-asserted-by":"publisher","first-page":"E779","DOI":"10.9778\/cmajo.20170123","volume":"5","author":"AM Cressman","year":"2017","unstructured":"Cressman AM, Mazereeuw G, Guan Q, Jia W, Gomes T, Juurlink DN. Availability of naloxone in Canadian pharmacies:a population-based survey. CMAJ Open. 2017;5(4):E779\u201384. Available from: http:\/\/cmajopen.ca\/content\/5\/4\/E779.full. [Cited 2021 Jan 7].","journal-title":"CMAJ Open."},{"key":"15554_CR26","doi-asserted-by":"publisher","first-page":"108238","DOI":"10.1016\/j.drugalcdep.2020.108238","volume":"216","author":"T Antoniou","year":"2020","unstructured":"Antoniou T, McCormack D, Campbell T, Sutradhar R, Tadrous M, Lum-Wilson N, et al. Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis. Drug Alcohol Depend. 2020;216:108238. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0376871620304038?via%3Dihub. [Cited 2021 Jan 7].","journal-title":"Drug Alcohol Depend."},{"issue":"3","key":"15554_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1177\/0091450917723350","volume":"44","author":"A Farrugia","year":"2017","unstructured":"Farrugia A, Fraser S, Dwyer R. Assembling the Social and Political Dimensions of Take-Home Naloxone. Contemp Drug Prob. 2017;44(3):163\u201375. Available from:\u00a0https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/0091450917723350. [Cited 2021 Jan 7].","journal-title":"Contemp Drug Prob."},{"issue":"22","key":"15554_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMsa1912403","volume":"382","author":"BR Cohen","year":"2020","unstructured":"Cohen BR, Mahoney KM, Baro E, Squire C, Beck M, Travis S, et al. FDA Initiative for Drug Facts Label for Over-the-Counter Naloxone. N Engl J Med. 2020;382(22):2129\u201336. Available from:\u00a0https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMsa1912403#article_citing_articles. [Cited 2021 Jan 7].","journal-title":"N Engl J Med."},{"key":"15554_CR29","unstructured":"Health Canada. Measuring the impact of the opioid overdose epidemic on life expectancy at birth in Canada - Canada.ca. Canada.ca. 2016. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-use\/problematic-prescription-drug-use\/opioids\/data-surveillance-research\/measuring-impact-on-life-expectancy.html. [Cited 2021 Jan 7]."},{"key":"15554_CR30","doi-asserted-by":"publisher","first-page":"102872","DOI":"10.1016\/j.drugpo.2020.102872","volume":"83","author":"AB Collins","year":"2020","unstructured":"Collins AB, Ndoye CD, Arene-Morley D, Marshall BDL. Addressing co-occurring public health emergencies: The importance of naloxone distribution in the era of COVID-19. Int J Drug Policy. 2020;83:102872. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7373067\/. [Cited 2021 Mar 15].","journal-title":"Int J Drug Policy."},{"issue":"6","key":"15554_CR31","first-page":"538","volume":"61","author":"P Leece","year":"2015","unstructured":"Leece P, Orkin A, Shahin R, Steele LS. Can naloxone prescription and overdose training for opioid users work in family practice? Perspectives of family physicians. Can Fam Physician Medecin de famille canadien. 2015;61(6):538\u201343. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4463897\/. [Cited 2021 Jan 7].","journal-title":"Can Fam Physician Medecin de famille canadien."},{"issue":"1","key":"15554_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1017\/cem.2017.390","volume":"20","author":"L Lacroix","year":"2017","unstructured":"Lacroix L, Thurgur L, Orkin AM, Perry JJ, Stiell IG. Emergency physicians\u2019 attitudes and perceived barriers to the implementation of take-home naloxone programs in Canadian emergency departments. CJEM 2017;20(1):46\u201352. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28918769\/. [Cited 2021 Jan 7].","journal-title":"CJEM"},{"issue":"1","key":"15554_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/160940690400300101","volume":"3","author":"S Thorne","year":"2004","unstructured":"Thorne S, Kirkham SR, O\u2019Flynn-Magee K. The Analytic Challenge in Interpretive Description. Int J Qual Methods. 2004;3(1):1\u201311.\u00a0Available from: https:\/\/doi.org\/10.1177%2F160940690400300101.","journal-title":"Int J Qual Methods."},{"issue":"2","key":"15554_CR34","first-page":"163","volume":"52","author":"C Spinuzzi","year":"2005","unstructured":"Spinuzzi C. The methodology of participatory design. Tech Commun. 2005;52(2):163\u201374. Available from: https:\/\/repositories.lib.utexas.edu\/bitstream\/handle\/2152\/28277\/SpinuzziTheMethodologyOfParticipatoryDesign.pdf.","journal-title":"Tech Commun."},{"key":"15554_CR35","volume-title":"Participatory Design of evidence-based online youth mental health promotion, intervention and treatment \/\/ A Young and Well Cooperative Research Centre innovative methodologies guide","author":"P Hagen","year":"2012","unstructured":"Hagen P, Collin P, Metcalf A, Nicholas M. Participatory Design of evidence-based online youth mental health promotion, intervention and treatment \/\/ A Young and Well Cooperative Research Centre innovative methodologies guide; 2012. Available from: https:\/\/researchdirect.westernsydney.edu.au\/islandora\/object\/uws:18814\/datastream\/PDF\/view."},{"key":"15554_CR36","volume-title":"Scandinavian Approaches to Participatory Design","author":"J Gregory","year":"2003","unstructured":"Gregory J. Scandinavian Approaches to Participatory Design . ResearchGate. unknown; 2003. Available from: https:\/\/www.researchgate.net\/publication\/228872045_Scandinavian_Approaches_to_Participatory_Design. [Cited 2021 Jan 7]."},{"key":"15554_CR37","unstructured":"Steen M, Manschot M, De Koning N. Benefits of Co-design in Service Design Projects. Int J Des. 2011. Available from: http:\/\/www.ijdesign.org\/index.php\/IJDesign\/article\/view\/890\/346. [Cited 2021 Jan 7]."},{"key":"15554_CR38","doi-asserted-by":"crossref","unstructured":"Donetto S, Pierri P, Tsianakas V, Robert G. Experience-based Co-design and Healthcare Improvement: Realizing Participatory Design in the Public Sector. ResearchGate. Bloomsbury Publishing; 2015. Available from: https:\/\/www.researchgate.net\/publication\/275153597_Experience-based_Co-design_and_Healthcare_Improvement_Realizing_Participatory_Design_in_the_Public_Sector. [Cited 2021 Jan 7].","DOI":"10.2752\/175630615X14212498964312"},{"key":"15554_CR39","doi-asserted-by":"crossref","unstructured":"Ferreira B, Conte T, Diniz Junqueira Barbosa S. Eliciting Requirements Using Personas and Empathy Map to Enhance the User Experience. IEEE Xplore. 2015. p. 80\u20139. Available from: https:\/\/ieeexplore.ieee.org\/abstract\/document\/7328012. [Cited 2020 Sep 4].","DOI":"10.1109\/SBES.2015.14"},{"key":"15554_CR40","unstructured":"Marquez JJ, Downey A, Clement R. Walking a Mile in the User\u2019s Shoes: Customer Journey Mapping as a Method to Understanding the User Experience. ResearchGate. Taylor & Francis (Routledge); 2015. Available from: https:\/\/www.researchgate.net\/profile\/Joe_Marquez2\/publication\/288006156_Walking_a_Mile_in_the_User. [Cited 2021 Jan 7]."},{"key":"15554_CR41","volume-title":"Addressing stigma and marginalisation in the design of naloxone packaging to support opiate overdose response","author":"K Sellen","year":"2018","unstructured":"Sellen K, Goso N, Hunt R, Orkin A. Addressing stigma and marginalisation in the design of naloxone packaging to support opiate overdose response. Sheffield, UK: Design4Health; 2018."},{"key":"15554_CR42","volume-title":"Co-design of a naloxone distribution kit for family practice, emergency departments, and addictions medicine","author":"K Sellen","year":"2018","unstructured":"Sellen K, Orkin A. Co-design of a naloxone distribution kit for family practice, emergency departments, and addictions medicine. Toronto, Canada: Family Medicine Forum; 2018."},{"key":"15554_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drugpo.2019.01.015","volume":"66","author":"T Antoniou","year":"2019","unstructured":"Antoniou T, Ala-Leppilampi K, Shearer D, Parsons JA, Tadrous M, Gomes T. \u201cLike being put on an ice floe and shoved away\u201d: a qualitative study of the impacts of opioid-related policy changes on people who take opioids. Int J Drug Policy. 2019;66:15\u201322. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0955395919300234. [Cited 2021 Jan 7].","journal-title":"Int J Drug Policy."},{"issue":"3","key":"15554_CR44","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/nur.4770160308","volume":"16","author":"M Sandelowski","year":"1993","unstructured":"Sandelowski M. Theory unmasked: The uses and guises of theory in qualitative research. Res Nurs Health. 1993;16(3):213\u20138. https:\/\/doi.org\/10.1002\/nur.4770160308.","journal-title":"Res Nurs Health."},{"key":"15554_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.socscimed.2013.07.035","volume":"103","author":"BG Link","year":"2014","unstructured":"Link BG, Phelan J. Stigma power. Soc Sci Med. 2014;103:24\u201332. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4451051\/39. [Cited 2021 Jan 7]. Bazeley P. Analysing qualitative data: More than \u2018identifying themes\u2019. Malaysian Journal of Qualitative Research. 2009 Jan;2(2):6\u201322.","journal-title":"Soc Sci Med."},{"key":"15554_CR46","first-page":"127","volume-title":"Doing qualitative research","author":"W Miller","year":"1999","unstructured":"Miller W, Crabtree B. The dance of interpretation. In: Crabtree B, Miller W, editors. Doing qualitative research. Thousand Oaks: Sage Publications; 1999. p. 127\u201343."},{"key":"15554_CR47","volume-title":"NVivo qualitative data analysis software. (Version 10)","author":"QSR International Pty Ltd","year":"2012","unstructured":"QSR International Pty Ltd. NVivo qualitative data analysis software. (Version 10). 2012."},{"issue":"6","key":"15554_CR48","doi-asserted-by":"publisher","first-page":"e004613","DOI":"10.1136\/bmjopen-2013-004613","volume":"4","author":"JA Parsons","year":"2014","unstructured":"Parsons JA, Baker NA, Smith-Gorvie T, Hudak PL. To \u201cGet by\u201d or \u201cget help\u201d? A qualitative study of physicians\u2019 challenges and dilemmas when patients have limited English proficiency. BMJ Open. 2014;4(6):e004613-3. Available from: https:\/\/bmjopen.bmj.com\/content\/4\/6\/e004613. [Cited 2021 Jan 7].","journal-title":"BMJ Open."},{"key":"15554_CR49","volume-title":"Constant Comparison Method: A Kaleidoscope of Data. NSUWorks","author":"JF Dye","year":"2015","unstructured":"Dye JF, Schatz IM, Rosenberg BA, Coleman ST. Constant Comparison Method: A Kaleidoscope of Data. NSUWorks. 2015. Available from: https:\/\/nsuworks.nova.edu\/tqr\/vol4\/iss1\/8\/. [Cited 2021 Jan 7]."},{"key":"15554_CR50","first-page":"239","volume":"26","author":"M McInnes","year":"1992","unstructured":"McInnes M. Good samaritan statutes: a summary and analysis. U Brit Colum L Rev. 1992;26:239.","journal-title":"U Brit Colum L Rev"},{"issue":"5","key":"15554_CR51","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1111\/hex.13559","volume":"25","author":"K Sellen","year":"2022","unstructured":"Sellen K, Goso N, Halleran L, Mulvale-Fletcher A, Sarmiento F, Ligabue F, Handford C, Klaiman M, Milos G, Wright A, Charles M, et al. Design details for overdose education and take-home naloxone kits: Codesign with family medicine, emergency department, addictions medicine and community. Health Expect. 2022;25(5):2440\u201352.","journal-title":"Health Expect"},{"key":"15554_CR52","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2017.06.005","volume":"46","author":"N Fairbairn","year":"2017","unstructured":"Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172\u20139. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5783633\/. [Cited 2021 Jan 7].","journal-title":"Int J Drug Policy"},{"key":"15554_CR53","unstructured":"McInnes M. Good Samaritan Statutes: A Summary and Analysis. U Brit Colum L Rev. 1992;26:239."},{"issue":"1","key":"15554_CR54","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1146\/annurev.soc.27.1.363","volume":"27","author":"BG Link","year":"2001","unstructured":"Link BG, Phelan JC. Conceptualizing stigma. Ann Rev Sociol. 2001;27(1):363\u201385.","journal-title":"Ann Rev Sociol"},{"key":"15554_CR55","volume-title":"Damaged identities, narrative repair","author":"NH Lindemann","year":"2001","unstructured":"Lindemann NH. Damaged identities, narrative repair. Ithaca: Cornell Univ. Press; 2001."},{"key":"15554_CR56","doi-asserted-by":"crossref","unstructured":"Harvey GS, Knox M, Hyshka E, Rowe A, Lefsrud L, Sommerfeldt S, Forhan M. Opioid overdose response and health information complexities: a pilot study on Naloxone kit design. J Health Design. 2021;6(2):391\u2013400.","DOI":"10.21853\/JHD.2021.135"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-15554-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-15554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T11:20:27Z","timestamp":1729423227000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-15554-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["15554"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-15554-6","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was approved by OCAD University and Unity Health\u2019s Ethics Review Boards. All participants in the data gathering process and co-design workshop received an Information Letter and Consent Form and informed consent was obtained from all participants. All research activities followed were performed in accordance with the relevant guidelines and regulations (Declaration of Helsinki).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The co-design process was deliberately structured to include community member (public) involvement with multiple opportunities for public contribution to the co-design process. In addition, patient\/public participation was a principle for the management and structuring of the research team.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient or public contribution"}}],"article-number":"888"}}